GlassScriptPhysician profile
Steve A Mora
NPI 1780747287
$73,548.19
in general payments reported to CMS, 2019-2025
40 companies · $24K in 2025
The $24K reported for 2025 was more than what 92% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $15K · 2021: $12K · 2022: $6,477 · 2023: $2,007 · 2024: $1,261 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Food and Beverage: $4,368 · Travel and Lodging: $2,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,775.00 |
| Food and Beverage | $4,368.15 |
| Travel and Lodging | $2,591.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intravu INC. | $41,000.00 | 2019-2022 | |
| Smith+Nephew, INC. | $25,268.69 | 2019-2025 | Q-Fix, Spatial Frame, Fast-Fix |
| Biotissue Holdings INC. | $1,976.66 | 2021-2025 | |
| Arthrex, INC. | $714.00 | 2021 | |
| Stryker Corporation | $567.27 | 2022-2025 | Inspace, Salvation, Graftjacket |
| Saxum Surgical, INC. | $449.17 | 2023-2024 | |
| Abbott Laboratories | $393.31 | 2021-2023 | Proclaim |
| Micromed INC | $356.12 | 2021 | |
| Depuy Synthes Sales INC. | $349.63 | 2019-2023 | Dynacord, Truespan Orthocord, Vapr |
| Miach Orthopaedics, INC. | $319.77 | 2023-2024 | |
| Bioventus LLC | $247.91 | 2019-2023 | Exogen Ultrasound Bone Healing System |
| Teva Pharmaceuticals USA, INC. | $228.16 | 2019 | |
| Vision Quest Industries INC. | $154.48 | 2024 | Avid Ct2 Nmes/Ifc Stimulator |
| Horizon Therapeutics Plc | $154.10 | 2022-2023 | Krystexxa |
| Catalyst Orthoscience | $127.79 | 2024 | Catalyst Csr Shoulder System, R1 Reverse Shoulder System |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linvatec Corporation | $126.55 | 2019-2024 | Biobrace 23mm |
| Janssen Pharmaceuticals, INC | $119.24 | 2019 | |
| Vericel Corporation | $101.03 | 2019 | |
| Merz North America, INC. | $78.22 | 2020 | |
| Electronic Waveform Lab, INC. | $74.23 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $63.74 | 2023-2024 | Zilretta, Iovera, Exparel |
| Abbvie INC. | $62.76 | 2023-2024 | |
| Fidia Pharma USA INC. | $58.14 | 2020-2025 | Hymovis, Triluron |
| Ethicon US, LLC | $57.31 | 2019-2023 | Dermabond Prineo |
| Amgen INC. | $48.71 | 2021-2024 | Krystexxa |
| Abiomed | $43.83 | 2024 | Impella |
| Sanofi-Aventis U.S. LLC | $42.57 | 2022 | |
| Curonix LLC | $42.49 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Ermi LLC | $41.18 | 2019-2020 | |
| Nalu Medical, INC. | $35.78 | 2023-2025 | Nalu Neurostimulation System |
| Ibsa Pharma INC. | $33.95 | 2023-2024 | Tirosint, Licart, Tirosint |
| Relievant Medsystems, INC. | $29.90 | 2023 | Intracept |
| Zimmer Biomet Holdings, INC. | $29.30 | 2021-2024 | Gel-One Cross-Linked Hyaluronate |
| Anika Therapeutics, INC. | $28.89 | 2020 | |
| Pacira Therapeutics, INC. | $27.15 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.63 | 2025 | Relistor |
| Avanos Medical | $22.46 | 2024 | Trivisc Sodium Hyaluronate |
| Moximed, INC | $20.93 | 2023 | Misha Knee System |
| Redhill Biopharma INC. | $14.78 | 2020 | |
| Baudax Bio INC. | $13.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,500.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Mora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.